恆泰艾普(300157.SZ):銀川中能所持股份被預吿多個司法拍賣 擬合計拍賣5300萬股
格隆匯9月1日丨恆泰艾普(300157.SZ)公佈,公司近日通過京東網絡司法拍賣平台、阿里巴巴司法拍賣網絡平台查詢到銀川中能新財科技有限公司所持恆泰艾普無限售流通股股票被預吿多個司法拍賣。具體拍賣公吿如下:

截至目前,銀川中能持有恆泰艾普7600萬股股票,佔公司總股本的比例為10.67%,此次公吿司法拍賣涉及5300萬股。
目前,銀川中能新財科技有限公司的實際控制權未發生變更,如果後期銀川中能所持上市公司股份被實行拍賣、變賣等處分措施,其實際控制權存在變更的風險。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.